EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
NodThera Announces Positive First-In-Human Data for Two Brain Penetrant NLRP3 Inflammasome Inhibitors
BOSTON, MA. – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from first-in-human studies
Kynos Therapeutics Announces a First-In-Human Phase I study of its Novel Small Molecule KMO Inhibitor, KNS366, is Underway
EDINBURGH UK – Kynos Therapeutics Ltd, a biotechnology company developing a portfolio of first in class kynurenine 3-monooxygenase (KMO) inhibitors, today announces that dosing is
Apellis Presents Phase 3 Functional Analyses of SYFVORE™ (pegcetacoplan injection) for Geographic Atrophy
WALTHAM, Mass., (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced post hoc analyses from the
Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
Edinburgh and Cambridge, UK, – Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered into a worldwide drug discovery collaboration agreement with
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
WALTHAM, Mass., (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug
Kynos Therapeutics Announces the Strengthening of its Board with the Appointment of Experienced Biotech Entrepreneur Jean Combalbert as Independent Chair
EDINBURGH, UK – Kynos Therapeutics Ltd, an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology, today announced the appointment
Dunad Therapeutics Appoints Michael Bonney as Chair of Board of Directors
Bonney brings over 30 years of life sciences industry leadership experience as company advances its covalent chemistry platform for targeted protein degradation and beyond CAMBRIDGE,
Nyra Medical Announces $20 Million Series A Financing for its Transcatheter Heart Valve Repair Technology
ATLANTA, GA — Nyra Medical, Inc., a medical device company that is developing a novel transcatheter mitral valve repair technology, today announced the closing of